Date: 10 Jul 2010
Molecular Testing in Lung Cancer: The Time Is Now
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Slebos RJ, Kibbelaar RE, Dalesio O, et al.: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561–565.PubMed
Horio Y, Takahashi T, Kuroishi T, et al.: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993, 53:1–4.PubMed
• Scagliotti GV, Parikh P, von Pawel J, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543–3551. This phase 3 study demonstrated that in patients with adenocarcinoma and large cell histology, overall survival was superior for cisplatin/pemetrexed versus cisplatin/gemcitabine compared to patients with squamous cell histology, for whom the opposite results were seen.CrossRefPubMed
Lord RV, Brabender J, Gandara D, et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286–2291.PubMed
Giovannetti E, Mey V, Nannizzi S, et al.: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005, 68:110–118.PubMed
Tokumo M, Toyooka S, Kiura K, et al.: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005, 11:1167–1173.PubMed
Eberhard DA, Johnson BE, Amler LC, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900–5909.CrossRefPubMed
•• Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947–957. The I-PASS study showed that gefitinib is superior to carboplatin-paclitaxel as first-line treatment in Asian patients with advanced lung adenocarcinoma and no/limited smoking history. PFS was significantly longer for EGFR-mutant tumors when treated with gefitinib versus chemotherapy, while the opposite held true for EGFR wild-type tumors.CrossRefPubMed
•Douillard JY, Shepherd FA, Hirsh V, et al.: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744–752. The INTEREST trial showed that patients with EGFR-mutated tumors had longer PFS with gefitinib versus docetaxel in the second-line setting.CrossRefPubMed
• Cappuzzo TC, Stelmakh L, Cicenas S, et al.: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009, 27(15s): abstract 8001. In the phase 3 SATURN trial, erlotinib was shown to produce prolonged PFS and overall survival when compared with placebo in the maintenance setting after first-line chemotherapy. The benefit was modest overall but very striking in patients with EGFR-mutant tumors.
Taguchi F, Solomon B, Gregorc V, et al.: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838–846.CrossRefPubMed
Carbone DP, Salmon JS, Billheimer D, et al.: VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009 Dec 24 (Epub ahead of print).
Linardou H, Dahabreh IJ, Kanaloupiti D, et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962–972.CrossRefPubMed
Shaw AT CD, Iafrate AJ, Dezube BJ, et al.: Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations. J Thorac Oncol 2009, 4:S305–S306.
Arqule Joins the Phase III Club. http://seekingalpha.com/article/198568-arqule-joins-the-phase-iii-club. Accessed April 13, 2010.
Reck M, von Pawel J, Zatloukal P, et al.: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010 Feb 11 (Epub ahead of print).
Dowlati A, Gray R, Sandler AB, et al.: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407–1412.CrossRefPubMed
BATTLE Trial Personalizes Lung Cancer Therapy [AACR press release]. April 18, 2010.
Marchetti A, Milella M, Felicioni L, et al.: Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11:1084–1092.PubMed
- Molecular Testing in Lung Cancer: The Time Is Now
Current Oncology Reports
Volume 12, Issue 5 , pp 335-348
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Non-small cell lung cancer
- Molecular testing
- EML4/ALK translocation
- Industry Sectors
- Author Affiliations
- 1. Division of Hematology/Oncology, New York Presbyterian Hospital, Columbia University Medical Center, 1130 St. Nicholas Avenue, 1002A, New York, NY, 10032, USA
- 2. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
- 3. Division of Pulmonary and Critical Care Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, 10032, USA